Clinical TrialApr 18, 2026, 01:31 PM
Pliant's PLN-101095 shows 89% tumor reduction in Phase 1 trial
AI Summary
Pliant Therapeutics announced updated data from its Phase 1 trial of PLN-101095, in combination with pembrolizumab, for patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. The data, presented at AACR, showed significant antitumor activity in heavily pretreated patients, including one confirmed complete response and two confirmed partial responses. Confirmed responders experienced an average 89% tumor reduction from baseline and a median 19 months on treatment. PLN-101095 was generally well tolerated across all doses evaluated.
Key Highlights
- Average maximum tumor reduction of 89% in confirmed responders.
- Median time on treatment for confirmed responders increased to 19 months.
- One complete and two partial responses reported in ICI-refractory patients.
- PLN-101095 was generally well tolerated with only 2 discontinuations due to adverse events.
- Responders showed 4- to 13-fold increases in plasma interferon gamma (IFN-\u03b3).